During the COVID-19 pandemic, many companies have been seeking an emergency use authorization (EUA) to push technologies onto the market that can help address the public health crisis. The EUA is granted when the benefits of the technology outweigh anticipated risks.
On May 21, regulatory experts Ed Dougherty, principal at Dougherty Consulting, and Peter Raymond, CEO of The New Bureau, will share their insights on how companies should be navigating the regulatory process with FDA, along with steps for implementing quality by design in crisis mode, and supply chain strategies for sourcing, manufacturing and distribution during the MedTech Intelligence Emergency Use Authorization Webinar. The event takes place from 1–2 pm ET. Don’t miss this opportunity to learn how your company can effectively push its product to the finish line. Register now!
Related Articles
-
“Approaches to Increasing Diversity in Clinical Research and Addressing Health Inequities” offers key recommendations for device manufacturers and developers on steps they can take to increase diversity in clinical research and address health equity.
-
On May 16-17, the MedTech Regulatory Intelligence Summit will bring regulatory affairs professionals and members of the FDA together for two days of education, discussion and networking as we look at challenges and best practices in navigating current and on…
-
Jordi labs and its team of Ph.D. analytical chemists developed a proprietary, multi-detector approach to ensure that all extractables are accurately characterized to comply with global materials testing regulatory requirements.
-
Device manufacturers and importers will have two years to modify their Quality Systems to meet the requirements of the QMSR rule by February 2, 2026.
